Studies show that inhibiting Gal-3 reduces microglial activation and slows the progression of AD, making Gal-3 a promising therapeutic target for neurodegenerative diseases such as Alzheimer’s [11]. The gene discussed is LGALS3; the disease is neurodegenerative disease.